literature

HIV mutation literature information.

HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors.

PMID: 16207371 2005 AIDS research and therapy

Result: In contrast, mutations shown to confer resistance to multiple NRTIs, including E89G, K65R and M184V displayed low levels of resistance to RT1t49 (2-5 fold), with

Table: M184V

Discussion: The results of RT1t49 susceptibility testing (Table 3) with the ddI/ddC-resistant L74V, 3TC-resistant M184V and the AZT-resistant T215Y/M41L RTs are in agreement with our previously published efficacy tests using Jurkat T cell lines expressing each of the three selected anti-RT RNA aptamers, in which all the RNA aptamers were able to efficiently suppress replication of drug-resistant HIV.

Detection of minor populations of drug-resistant HIV-1 in acute seroconverters.

PMID: 16227789 2005 AIDS (London, England)

Abstract: Minor populations of drug-resistant variants were detected by quantitative real-time polymerase chain reaction using allele-discriminating oligonucleotides for three key resistance mutations: L90M (protease), K103N and M184V (reverse transcriptase).

Abstract: The L90M mutation was found in one of 49 (2%), the K103N mutation in five of 49 (10.2%) and the M184V mutation in six of 49 (12.2%) patients, respectively.

In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs.

PMID: 16245645 2005 Antiviral chemistry & chemotherapy

Abstract: M184V addition reduced SPD754 susceptibility by 1.8-fold in the presence or absence of TAMs.

Abstract: SPD754 retains a substantial proportion of its antiviral activity against HIV-1 containing multiple TAMs, with or without the M184V mutation.

Borano-nucleotides: new analogues to circumvent HIV-1 RT-mediated nucleoside drug-resistance.

PMID: 16247962 2005 Nucleosides, nucleotides & nucleic acids

Abstract: This suppression is also observed with BH3-d4T and BH3-3TC toward their clinically relevant mutants Q151M and M184V.

Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico.

PMID: 16268822 2005 HIV medicine

Abstract: For nucleoside inhibitors, mutations T215Y/C and F77L (3%) and D67N/S, T69N and M184V (2%), were detected.

The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS.

PMID: 16305515 2005 Current pharmaceutical design

Abstract: The M184V mutation appears to be the cornerstone of higher level resistance in regimens containing abacavir, imparting a 2-4 fold reduction in the susceptibility of HIV to abacavir.

Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs.

PMID: 16369374 2005 MedGenMed

Abstract: Among mutations that confer resistance to antiretroviral drugs, M184V was present in 76% of treated patients and K70R in 31% (A-->G transitions).

Full sequence of HIV type 1 Korean subtype B in an AIDS case with atypical seroconversion: TAAAA at TATA box.

PMID: 16386114 2005 AIDS research and human retroviruses

Abstract: The major differences in the level of the HIV-1 gene between the seronegative and seropositive states were changes at the glycosylation site (NXT) next to the inserted proline and many resistance mutations including M184V to antiretroviral drugs occurred.

Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.

PMID: 16452063 2005 HIV clinical trials

Abstract: 14 pts with K65R and M184V/I were given a rescue therapy with a successful outcome (< 50 copies/mL; median follow-up 48 weeks).

Abstract: 76% of pts developed K65R and M184V/I mutations by W24, and 19% developed M184V/I alone.

Abstract: CONCLUSION: Convergent genetic pathway to resistance, in conjunction with lower antiretroviral potency, may explain the high rate of selection K65R and M184V mutations.

Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures.

PMID: 16553322 2005 Revista do Instituto de Medicina Tropical de Sao Paulo

Abstract: The most frequent mutations were M41L, M184V, and T215FY in RT and L62PI, L10FIRV and M36I in PT.

Browser Board

Co-occurred Entities

Filtrator